Top

Current Cardiology Reports

Published in:

01-11-2018 | Stroke (JF Meschia, Section Editor)

Atrial Cardiopathy and Stroke Prevention

Author: Mitchell S. V. Elkind

Published in: Current Cardiology Reports | Issue 11/2018

Abstract

Purpose of Review

Many patients with ischemic stroke have a stroke syndrome and neuroimaging findings consistent with embolism, but no evidence of atrial fibrillation. Recent data suggest that the pathological atrial substrate, or atrial cardiopathy, that underlies atrial fibrillation, rather than atrial fibrillation itself, may be an important cause of unexplained strokes. This paper will review the literature on the rationale and data behind the concept of atrial cardiopathy, its pathophysiology, suggested biomarkers of atrial cardiopathy, and therapeutic implications.

Recent Findings

Several lines of evidence suggest that patients can have strokes associated with disorders of the atrium, even without frank atrial fibrillation. Even in patients with paroxysmal atrial fibrillation, cardiac emboli may occur temporally disassociated from episodes of atrial fibrillation, and the left atrial appendage flow patterns associated with increased thromboembolic risk may occur even when the surface electrocardiogram demonstrates normal sinus rhythm. Biomarkers of left atrial structural and electrophysiological abnormalities have been associated with stroke risk, even in the absence of atrial fibrillation.

Summary

Atrial cardiopathy, as determined by the presence of biomarkers of left atrial dysfunction, may provide a therapeutic target to reduce the risk of cardioembolic stroke in the absence of atrial fibrillation. Clinical trials are currently ongoing to test this hypothesis.

Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source: a systematic review and clinical update. Stroke. 2017;48:867–72.PubMed

•• Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13:429–38. This classic paper provided the rationale for the new concept of embolic stroke of undetermined source (or ESUS), an updated definition for cryptogenic stroke emphasizing the importance of a full diagnostic evaluation for all stroke patients. PubMed

Lamy C, Giannesini C, Zuber M, Arquizan C, Meder JF, Trystram D, et al. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA study. Stroke. 2002;33:706–11.PubMed

Thaler DE, Ruthazer R, Di Angelantonio E, Di Tullio MR, Donovan JS, Elkind MS, et al. Neuroimaging findings in cryptogenic stroke patients with and without patent foramen ovale. Stroke. 2013;44(3):675–80.PubMedPubMedCentral

•• Goldberger JJ, Arora R, Green D, Greenland P, Lee DC, Lloyd-Jones DM, et al. Evaluating the atrial myopathy underlying atrial fibrillation: identifying the arrhythmogenic and thrombogenic substrate. Circulation. 2015;132:278–91. Review of the mechanisms of thromboembolism in patients with atrial fibrillation. PubMedPubMedCentral

•• Dzeshka MS, Lip GY, Snezhitskiy V, Shantsila E. Cardiac fibrosis in patients with atrial fibrillation: mechanisms and clinical implications. J Am Coll Cardiol. 2015;66:943–59. Review of the fundamentsal role of atrial fibrosis in causing atrial fibrillation. PubMed

Li Q, Liu X, Wei J. Ageing related periostin expression increase from cardiac fibroblasts promotes cardiomyocytes senescent. Biochem Biophys Res Commun. 2014;452:497–502.PubMed

Wu J, Xia S, Kalionis B, Wan W, Sun T. The role of oxidative stress and inflammation in cardiovascular aging. Biomed Res Int. 2014;2014:615312. https://doi.org/10.1155/2014/615312.

•• Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015;12:230–43. Review of the role of inflammation in atrial fibrillation by leaders in the field. PubMed

10.

Jalife J. Mechanisms of persistent atrial fibrillation. Curr Opin Cardiol. 2014;29:20–7.PubMed

11.

Daccarett M, Badger TJ, Akoum N, Burgon NS, Mahnkopf C, Vergara G, et al. Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. J Am Coll Cardiol. 2011;57(7):831–8.PubMedPubMedCentral

12.

Markl M, Carr M, Ng J, Lee DC, Jarvis K, Carr J, et al. Assessment of left and right atrial 3D hemodynamics in patients with atrial fibrillation: a 4D flow MRI study. Int J Cardiovasc Imaging. 2016;32(5):807–15.PubMed

13.

Handke M, Harloff A, Hetzel A, Olschewski M, Bode C, Geibel A. Left atrial appendage flow velocity as a quantitative surrogate parameter for thromboembolic risk: determinants and relationship to spontaneous echocontrast and thrombus formation—a transesophageal echocardiographic study in 500 patients with cerebral ischemia. J Am Soc Echocardiogr. 2005;18(12):1366–72.PubMed

14.

Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366(2):120–9.PubMed

15.

• Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014;129:2094–9. One of the key papers demonstrating the temporal disassociation between the onset of atrial fibrillation and stroke. PubMed

16.

• Swiryn S, Orlov MV, Benditt DG, DiMarco JP, Lloyd-Jones DM, Karst E, et al. Clinical implications of brief device-detected atrial tachyarrhythmias in a cardiac rhythm management device population: results from the Registry of Atrial Tachycardia and Atrial Fibrillation Episodes. Circulation. 2016;134:1130–40. In this prospective registry, patients with short episodes of AF were not more likely than those without to have clinical events, supporting the concept of atrial burden. PubMed

17.

Flaker GC, Belew K, Beckman K, Vidaillet H, Kron J, Safford R, et al. Asymptomatic atrial fibrillation: demographic features and prognostic information from the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Am Heart J. 2005;149:657–63.PubMed

18.

•• Chen LY, Chung MK, Allen LA, Ezekowitz M, Furie KL, McCabe P, et al. Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement From the American Heart Association. Circulation. 2018;137(20):e623–44. This excellent scientific statement from thought leaders in the field reviews the concept of atrial fibrillation as a continuous, rather than dichotomous measure of disease activity. PubMed

19.

Boriani G, Glotzer TV, Santini M, West TM, De Melis M, Sepsi M, et al. Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J. 2014;35:508–16.PubMed

20.

•• Kamel H, Okin PM, Elkind MS, Iadecola C. Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke. 2016;47:895–900. This paper outlines the rationale for the concept of atrial cardiopathy, using an epidemiological approach. PubMedPubMedCentral

21.

Daoud EG, Glotzer TV, Wyse DG, Ezekowitz MD, Hilker C, Koehler J, et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of trends. Heart Rhythm. 2011;8:1416–23.PubMed

22.

Martin DT, Bersohn MM, Waldo AL, Wathen MS, Choucair WK, Lip GY, et al. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. Eur Heart J. 2015 Jul 7;36(26):1660–8.PubMed

23.

Hamer ME, Wilkinson WE, Clair WK, Page RL, McCarthy EA, Pritchett EL. Incidence of symptomatic atrial fibrillation in patients with paroxysmal supraventricular tachycardia. J Am Coll Cardiol. 1995;25:984–8.PubMed

24.

Kamel H, Elkind MS, Bhave PD, Navi BB, Okin PM, Iadecola C, et al. Paroxysmal supraventricular tachycardia and the risk of ischemic stroke. Stroke. 2013;44:1550–4.PubMedPubMedCentral

25.

• Larsen BS, Kumarathurai P, Falkenberg J, Nielsen OW, Sajadieh A. Excessive atrial ectopy and short atrial runs increase the risk of stroke beyond incident atrial fibrillation. J Am Coll Cardiol. 2015;66(3):232–41. An important paper demonstrating the relationship of atrial ectopy, short of atrial fibrillation, to stroke risk. PubMed

26.

• Yamada S, Lin CY, Chang SL, Chao TF, Lin YJ, Lo LW, et al. Risk of stroke in patients with short-run atrial tachyarrhythmia. Stroke. 2017;48(12):3232–8. This large study demonstrated that patients with atrial ectopy are at increased stroke risk, even in absence of known AF. PubMed

27.

Bellotti P, Spirito P, Lupi G, Vecchio C. Left atrial appendage function assessed by transesophageal echocardiography before and on the day after elective cardioversion for nonvalvular atrial fibrillation. Am J Cardiol. 1998;81:1199–202.PubMed

28.

Warraich HJ, Gandhavadi M, Manning WJ. Mechanical discordance of the left atrium and appendage: a novel mechanism of stroke in paroxysmal atrial fibrillation. Stroke. 2014;45:1481–4.PubMed

29.

Kääb S, Darbar D, van Noord C, Dupuis J, Pfeufer A, Newton-Cheh C. Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J. 2009;30(7):813–9.PubMedPubMedCentral

30.

Gretarsdottir S, Thorleifsson G, Manolescu A, Styrkarsdottir U, Helgadottir A, Gschwendtner A, et al. Risk variants for atrial fibrillation on chromosome 4q25 associate with ischemic stroke. Ann Neurol. 2008;64:402–9.PubMed

31.

Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61(2):755–9.PubMed

32.

Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol. 1995;25:452–9.PubMed

33.

•• Yaghi S, Song C, Gray WA, Furie KL, Elkind MSV, Kamel H. Left atrial appendage function and stroke risk. Stroke. 2015;46(12):3554–9. This paper reviews the structure and function of the left atrial appendage and its potential role in causing stroke in patients with and without atrial fibrillation PubMedPubMedCentral

34.

Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (the Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr. 1999;12:1080–7.PubMed

35.

• Lee JM, Seo J, Uhm JS, Kim YJ, Lee HJ, Kim JY, et al. Why is left atrial appendage morphology related to strokes? An analysis of the flow velocity and orifice size of the left atrial appendage. J Cardiovasc Electrophysiol. 2015;26(9):922–7. This study provides evidence of the importance of left atrial appendage morphology to stroke risk. PubMed

36.

Beigel R, Wunderlich NC, Ho SY, Arsanjani R, Siegel RJ. The left atrial appendage: anatomy, function, and noninvasive evaluation. JACC Cardiovasc Imaging. 2014;7:1251–65.PubMed

37.

Veinot JP, Harrity PJ, Gentile F, Khandheria BK, Bailey KR, Eickholt JT, et al. Anatomy of the normal left atrial appendage: a quantitative study of age-related changes in 500 autopsy hearts: implications for echocardiographic examination. Circulation. 1997;96:3112–5.PubMed

38.

• Yamamoto M, Seo Y, Kawamatsu N, Sato K, Sugano A, Machino-Ohtsuka T, et al. Complex left atrial appendage morphology and left atrial appendage thrombus formation in patients with atrial fibrillation. Circ Cardiovasc Imaging. 2014;7:337–43. This study provides evidence of the importance of left atrial appendage morphology to stroke risk. PubMed

39.

• Petersen M, Roehrich A, Balzer J, Shin DI, Meyer C, Kelm M, et al. Left atrial appendage morphology is closely associated with specific echocardiographic flow pattern in patients with atrial fibrillation. Europace. 2015;17:539–45. This study provides evidence of the importance of left atrial appendage morphology to stroke risk. PubMed

40.

Di Biase L, Santangeli P, Anselmino M, Mohanty P, Salvetti I, Gili S, et al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol. 2012;60:531–8.PubMed

41.

• Anselmino M, Scaglione M, Di Biase L, Gili S, Santangeli P, Corsinovi L, et al. Left atrial appendage morphology and silent cerebral ischemia in patients with atrial fibrillation. Heart Rhythm. 2014;11:2–7. This study provides evidence of the importance of left atrial appendage morphology to risk of silent cerebral ischemia in patients with atrial fibrillation. PubMed

42.

Khurram IM, Dewire J, Mager M, Maqbool F, Zimmerman SL, Zipunnikov V, et al. Relationship between left atrial appendage morphology and stroke in patients with atrial fibrillation. Heart Rhythm. 2013;10:1843–9.PubMed

43.

• Fukushima K, Fukushima N, Kato K, Ejima K, Sato H, Fukushima K, et al. Correlation between left atrial appendage morphology and flow velocity in patients with paroxysmal atrial fibrillation. Eur Heart J Cardiovasc Imaging. 2016;17(1):59–66. This cross-sectional study showed that patients with chicken wing morphology LAA had increased LAA flow velocity, making them less likely to have thrombi. PubMed

44.

• Kishima H, Mine T, Ashida K, Sugahara M, Kodani T, Masuyama T. Does left atrial appendage morphology influence left atrial appendage flow velocity? Circ J. 2015;79(8):1706–11. This study provides important physiological confirmation of the mechanisms by which non-chicken wing morphology of the LAA is associated with increased stroke risk PubMed

45.

Lee JM, Shim J, Uhm JS, Kim YJ, Lee HJ, Pak HN, et al. Impact of increased orifice size and decreased flow velocity of left atrial appendage on stroke in nonvalvular atrial fibrillation. Am J Cardiol. 2014;113:963–9.PubMed

46.

Rizos T, Guntner J, Jenetzky E, Marquardt L, Reichardt C, Becker R, et al. Continuous stroke unit electrocardiographic monitoring versus 24-hour holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. Stroke. 2012;43:2689–94.PubMed

47.

Bhatt A, Majid A, Razak A, Kassab M, Hussain S, Safdar A. Predictors of occult paroxysmal atrial fibrillation in cryptogenic strokes detected by long-term noninvasive cardiac monitoring. Stroke Res Treat. 2011;2011:172074.PubMedPubMedCentral

48.

Rojo-Martinez E, Sandin-Fuentes M, Calleja-Sanz AI, Cortijo-Garcia E, Garcia-Bermejo P, Ruiz-Pinero M, et al. High performance of an implantable Holter monitor in the detection of concealed paroxysmal atrial fibrillation in patients with cryptogenic stroke and a suspected embolic mechanism. Rev Neurol. 2013;57:251–7.PubMed

49.

•• Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370:2467–77. One of the two landmark clinical trials demonstrating the benefits of long-term cardiac monitoring for atrial fibrillation among patients with unexplained stroke. PubMed

50.

•• Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370:2478–86. The other of the two landmark clinical trials demonstrating the benefits of long-term cardiac monitoring for atrial fibrillation among patients with unexplained stroke. PubMed

51.

Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–236.PubMed

52.

Wozakowska-Kaplon B. Changes in left atrial size in patients with persistent atrial fibrillation: a prospective echocardiographic study with a 5-year follow-up period. Int J Cardiol. 2005;101:47–52.PubMed

53.

Benjamin EJ, D’Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation. 1995;92:835–41.PubMed

54.

Di Tullio MR, Sacco RL, Sciacca RR, Homma S. Left atrial size and the risk of ischemic stroke in an ethnically mixed population. Stroke. 1999;30:2019–24.PubMed

55.

• Yaghi S, Moon YP, Mora-McLaughlin C, Willey JZ, Cheung K, Di Tullio MR, et al. Left atrial enlargement and stroke recurrence: The Northern Manhattan Stroke Study. Stroke. 2015;46:1488–93. A population-based study demonstrating that left atrial size predicts stroke recurrence, even among patients without atrial fibrillation. PubMedPubMedCentral

56.

Hancock EW, Deal BJ, Mirvis DM, Okin P, Kligfield P, Gettes LS, et al. AHA/ACC/HRS recommendations for the standardization and interpretation of the electrocardiogram: Part V: electrocardiogram changes associated with cardiac chamber hypertrophy. Circulation. 2009;119:e251–61.PubMed

57.

Tiffany Win T, Ambale Venkatesh B, Volpe GJ, Mewton N, Rizzi P, Sharma RK, et al. Associations of electrocardiographic P-wave characteristics with left atrial function, and diffuse left ventricular fibrosis defined by cardiac magnetic resonance: the PRIMERI study. Heart Rhythm. 2015;12:155–62.PubMed

58.

Soliman EZ, Prineas RJ, Case LD, Zhang ZM, Goff DC Jr. Ethnic distribution of ECG predictors of atrial fibrillation and its impact on understanding the ethnic distribution of ischemic stroke in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2009;40:1204–11.PubMedPubMedCentral

59.

• Kamel H, Soliman EZ, Heckbert SR, Kronmal RA, Longstreth WT Jr, Nazarian S, et al. P-wave morphology and the risk of incident ischemic stroke in the Multi-Ethnic Study of Atherosclerosis. Stroke. 2014;45:2786–8. One of the studies demonstrating that P wave characteristics can be used as a measure of the risk of stroke, even independently of atrial fibrillation being present. PubMedPubMedCentral

60.

• Kamel H, O'Neal WT, Okin PM, Loehr LR, Alonso A, Soliman EZ. Electrocardiographic left atrial abnormality and stroke subtype in the Atherosclerosis Risk in Communities study. Ann Neurol. 2015;78:670–8. A study demonstrating that P wave characteristics can be used as a measure of the risk of stroke, and particularly cardioembolic stroke. PubMedPubMedCentral

61.

• Kamel H, Hunter M, Moon YP, Yaghi S, Cheung K, Di Tullio MR, et al. Electrocardiographic left atrial abnormality and risk of stroke: Northern Manhattan Study. Stroke. 2015;46:3208–12. Another of the studies demonstrating that P wave characteristics can be used as a measure of the risk of stroke, even independently of a history of atrial fibrillation. PubMedPubMedCentral

62.

• Kamel H, Bartz TM, Longstreth WT Jr, Okin PM, Thacker EL, Patton KK, et al. Association between left atrial abnormality on ECG and vascular brain injury on MRI in the Cardiovascular Health Study. Stroke. 2015;46:711–6. Observational study showing that atrial cardiuopathy biomarkers are associated with subclinical cerebrovascular disease. PubMedPubMedCentral

63.

Cheng S, Keyes MJ, Larson MG, McCabe EL, Newton-Cheh C, Levy D, et al. Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA. 2009;301(24):2571–7.PubMedPubMedCentral

64.

• Thijs VN, Brachmann J, Morillo CA, Passman RS, Sanna T, Bernstein RA, et al. Predictors for atrial fibrillation detection after cryptogenic stroke: results from CRYSTAL AF. Neurology. 2016;86(3):261–9. This study provides evidence that certain atrial cardiopathy biomarkers are predictive of detection of AF after unexplained stroke. PubMedPubMedCentral

65.

Montalvo M, Tadi P, Merkler A, Gialdini G, Martin-Schild S, Navalkele D, et al. PR interval prolongation and cryptogenic stroke: a multicenter retrospective study. J Stroke Cerebrovasc Dis. 2017;26(10):2416–20.PubMed

66.

•• Yaghi S, Liberman AL, Atalay M, Song C, Furie KL, Kamel H, et al. Cardiac magnetic resonance imaging: a new tool to identify cardioaortic sources in ischaemic stroke. J Neurol Neurosurg Psych. 2017;88:31–7. Excellent review of cardiac MR as a way of assessing for atrial cardiopathy.

67.

Oldgren J, Hijazi Z, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, et al. performance and validation of a novel biomarker-based stroke risk score for atrial fibrillation. Circulation. 2016;134(22):1697–707.PubMed

68.

Rutten JH, Mattace-Raso FU, Steyerberg EW, Lindemans J, Hofman A, Wieberdink RG, et al. Amino-terminal pro-B-type natriuretic peptide improves cardiovascular and cerebrovascular risk prediction in the population: the Rotterdam study. Hypertension. 2010;55:785–91.PubMed

69.

Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA. 2005;293:1609–16.PubMed

70.

Dadu RT, Fornage M, Virani SS, Nambi V, Hoogeveen RC, Boerwinkle E, et al. Cardiovascular biomarkers and subclinical brain disease in the Atherosclerosis Risk in Communities study. Stroke. 2013;44:1803–8.PubMedPubMedCentral

71.

• Llombart V, Antolin-Fontes A, Bustamante A, Giralt D, Rost NS, Furie K, et al. B-type natriuretic peptides help in cardioembolic stroke diagnosis: pooled data meta-analysis. Stroke. 2015;46:1187–95. This study provides evidence for the benefit of serum biomarkers in stroke subtype diagnosis. PubMed

72.

Rodriguez-Yanez M, Arias-Rivas S, Santamaria-Cadavid M, Sobrino T, Castillo J, Blanco M. High pro-BNP levels predict the occurrence of atrial fibrillation after cryptogenic stroke. Neurology. 2013;81:444–7.PubMed

73.

Cushman M, Judd SE, Howard VJ, Kissela B, Gutierrez OM, Jenny NS, et al. N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort. Stroke. 2014;45:1646–50.PubMedPubMedCentral

74.

Berntsson J, Zia E, Borne Y, Melander O, Hedblad B, Engstrom G. Plasma natriuretic peptides and incidence of subtypes of ischemic stroke. Cerebrovasc Dis. 2014;37:444–50.PubMed

75.

Folsom AR, Nambi V, Bell EJ, Oluleye OW, Gottesman RF, Lutsey PL, et al. Troponin t, n-terminal pro-b-type natriuretic peptide, and incidence of stroke: the Atherosclerosis Risk in Communities Study. Stroke. 2013;44:961–7.PubMedPubMedCentral

76.

de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304:2503–12.PubMedPubMedCentral

77.

Daniels LB, Laughlin GA, Clopton P, Maisel AS, Barrett-Connor E. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo study. J Am Coll Cardiol. 2008;52:450–9.PubMedPubMedCentral

78.

Kamel H, Longstreth WT, Tirschwell DL, Kronmal RA, Broderick JP, Palesch YY, et al. AtRial Cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke (ARCADIA) trial: rationale and methods. Int J Stroke. (In press)

79.

• Kamel H, Bartz TM, Elkind MSV, Okin PM, Thacker EL, Patton KK, et al. Atrial Cardiopathy and the Risk of Ischemic Stroke in the CHS (Cardiovascular Health Study). Stroke. 2018;49(4):980–6. In this epidemiological study, the authors compare the predictive value of several atrial cardiopathy biomarkers. PubMed

80.

Yaghi S, Boehme AK, Hazan R, Hod EA, Canaan A, Andrews HF, et al. Atrial cardiopathy and cryptogenic stroke: a cross-sectional pilot study. J Stroke Cerebrovasc Dis. 2016;25:110–4.PubMed

81.

• Sebasigari D, Merkler A, Guo Y, Gialdini G, Kummer B, Hemendinger M, et al. Biomarkers of atrial cardiopathy and atrial fibrillation detection on mobile outpatient continuous telemetry after embolic stroke of undetermined source. J Stroke Cerebrovasc Dis. 2017;26(6):1249–53. This study shows how biomarkers of atrial cardiopathy can be used to predict which patients with unexplained stroke will have atrial fibrillation detected on monitoring. PubMed

82.

van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288:2441–8.PubMed

83.

Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–62.PubMed

84.

Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366:1859–69.PubMedPubMedCentral

85.

Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89:635–41.PubMed

86.

Vaitkus PT, Barnathan ES. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. J Am Coll Cardiol. 1993;22:1004–9.PubMed

87.

•• Longstreth WT Jr, Kronmal RA, Thompson JL, Christenson RH, Levine SR, Gross R, et al. Amino terminal pro-b-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy. Stroke. 2013;44:714–9. This tertiary analysis of the Warfarin-Aspirin Recurrent Stroke Study provides preliminary evidence that anticoagulation may be of benefit for patients with atrial cardiopathy. PubMedPubMedCentral

88.

•• Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378(23):2191–201. The RESPECT-ESUS trial tested the hypothesis that the direct-acting oral anticoagulant rivaroxaban would be superior to aspirin for patients with embolic stroke of undetermined source. The trial did not show any evidence of benefit of rivaroxaban over aspirin among these patients, leaving open the possibility that there may still be benefit among patients with atrial cardiopathy.

89.

Lopes RD, Alings M, Connolly SJ, Beresh H, Granger CB, Mazuecos JB, et al. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. Am Heart J. 2017;189:137–45.PubMed

Title: Atrial Cardiopathy and Stroke Prevention
Author: Mitchell S. V. Elkind
Publication date: 01-11-2018
Publisher: Springer US
Published in: Current Cardiology Reports / Issue 11/2018
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-018-1053-0

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Atrial Cardiopathy and Stroke Prevention

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 11/2018

Role of Percutaneous Chronic Total Occlusion Interventions in Patients with Ischemic Cardiomyopathy and Reduced Left Ventricular Ejection Fraction

Skeletal Muscle Myopathy in Heart Failure: the Role of Ejection Fraction

Transcatheter Mitral Valve Therapy: Defining the Patient Who Will Benefit

Role of Cardiac Magnetic Resonance Imaging in Valvular Heart Disease: Diagnosis, Assessment, and Management

Update on Devices for Diastolic Dysfunction: Options for a No Option Condition?

Type D Personality as a Risk Factor in Coronary Heart Disease: a Review of Current Evidence

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page